Radiation Oncology Journal

  • 제25권1호
  • /
  • Pages.43-53
  • /
  • 2007
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지

비인강암에서 예후인자로서의 EGFR, p53, Cox-2, Bcl-2 단백발현

EGFR, p53, Cox-2 and Bcl-2 Expression in Nasopharyngeal Carcinoma and Their Potential Clinical Implication

  • 채수민 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 이연수 (가톨릭대학교 의과대학 병리학교실) ;
  • 노광원 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 정수미 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 윤세철 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 장홍석 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 김연실 (가톨릭대학교 의과대학 방사선종양학교실)
  • Chae, Soo-Min (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Lee, Youn-Soo (Departments of Pathology, The Catholic University of Korea College of Medicine) ;
  • Roh, Kwang-Won (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Chung, Su-Mi (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Yoon, Sei-Chul (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Jang, Hong-Seok (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Kim, Yeon-Sil (Departments of Radiation Oncology, The Catholic University of Korea College of Medicine)
  • 발행 : 2007.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 비인강암종 환자들의 종양조직으로부터 EGFR, p53, Cox-2, Bcl-2 단백발현정도를 측정하고 임상양상, 치료성적과의 관련성을 조사하여 이들 단백이 치료에 대한 반응 및 예후를 예측할 수 있는 생물학적 표지자(biomarker)로 이용할 수 있는지 알아보고자 하였다. 대상 및 방법: 1988년 3월 1일부터 2002년 8월 15일까지 성모병원과 강남성모병원에서 비인강암으로 진단받고 근치적 방사선치료와 항암치료를 받았던 환자 104명 중 파라핀 블록이 보존되어 있는 75명을 대상으로 하여 후향적 분석을 시행하였다. 병기는 2002년에 개정된 AJCC로 재분류하였으며, 대상환자의 Hematoxylin-Eosin 염색 슬라이드를 두경부 병리 전문의사가 재검토하여 WHO 분류에 맞게 환자군을 분류하였으며 역형성(anaplasia) 유무, 유사분열(mitosis) 빈도 측정 등 병리조직학적 소견을 확인하였다. EGFR, p53, Cox-2, Bcl-2 단백발현 정도를 면역조직 화학염색을 통해 측정하였으며 이들 단백의 발현정도와 임상병기, 치료성적과의 관련성을 조사하였다. 결 과: 전체 104명 환자의 추적기간은 $5.5{\sim}201$개월이었고 3년 생존율은 68.7%, 5년 생존율은 53.5%, 중앙생존기간은 85.5개월이었으며 3년 무병생존율은 68.2%, 5년 무병생존율은 51.5%, 중앙무병생존기간은 61.1개월이었다. WHO 분류 2와 3 종양은 완전관해율이 높아 항암방사선치료(chemoradiotherapy)에 대한 반응성이 높은 경향을 보였으며(p=0.075), 상대적으로 진단당시 림프절전이율이 높았고, 원격전이할 확률이 높았다. p53은 발현 정도가 증가함에 따라 생존율이 떨어지고 유사분열은 증가하였다. Bcl-2 발현이 증가함에 따라 재발률이 떨어지는 경향을 보였으며, WHO 분류와 연관성을 보였다. Cox-2의 발현이 증가함에 따라 생존율이 떨어지고, 림프절치료율도 낮은 것으로 나타났다. 그러나 EGFR은 어떤 인자와도 상관관계를 보이지 않았다. 결 론: 비인강암에서 치료 후 예후를 예측할 수 있는 생물학적 표지자의 가능성을 가진 것으로 보고되고 있는 Cox-2, p53, Bcl-2, EGFR에 대한 연구결과 Cox-2, p53, Bcl-2의 발현정도는 항암방사선치료후 반응률, 생존율, 재발률과 연관을 보여 향후 치료결과를 예측할 수 있는 예후인자로서의 이용가능성이 있음을 알 수 있었으며 보다 실용적인 생물학적 표지자의 규명을 위해서 향후 보다 많은 환자를 대상으로 한 전향적 연구가 필요할 것으로 생각된다.

[ $\underline{Purpose}$ ]: To evaluate the relationship between the expression of EGFR, p53, Cox-2, Bcl-2 and the clinical parameters of NPC (nasopharyngeal carcinoma) patients treated with radiotherapy with/without chemotherapy, and to determine if these could be used as a biologic marker. $\underline{Materials\;and\;Methods}$: This study retrospectively examined 75 NPC patients who were pathologically diagnosed at St. Mary's Hospital and Kangnam St Mary's Hospital from March 1988 to August 2002 and treated with radiotherapy with/without chemotherapy. The levels of EGFR, p53, Cox-2, and Bcl-2 expression were determined immunohistochemically. The relationship between the levels of EGFR, p53, Cox-2 and Bcl-2 expression and the H- E staining findings including the WHO classification, TNM stage, tumor response to chemotherapy and radiotherapy, disease free survival (DFS), and overall survival (OS) was analyzed. $\underline{Results}$: At a median follow up of 50.8 months (range: $5.5{\sim}201$ months), the 3 years OS rate and PFS rate were 68.7% and 68.2%, respectively. The five year OS rate and PFS rate were 53.5% and 51.1%, respectively. The median OS duration and PFS duration were 85.5 months and 61.1 months, respectively. The WHO classification correlated with the complete response rate, lymph node metastasis and distant metastasis. The expression of p53 was associated with increased mitosis and poor overall survival. The expression of Bcl-2 correlated with the DFS and WHO classification. The expression of Cox-2 correlated with a poor overall survival and response rate in the lymph node. However, EGFR was not correlated with any factors. $\underline{Conclusion}$: These results suggest that the expression of p53, Cox-2, Bcl-2 plays role in predicting prognostic factors for NPC treated with radiotherapy with/without chemotherapy. However, further study on a larger number of patients will be needed to identify more useful biomarkers of NPC.

키워드

참고문헌

  1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041- 2054 https://doi.org/10.1016/S0140-6736(05)66698-6
  2. Jeon YK, Lee BY, Kim JE, Lee SS, Kim CW. Molecular characterization of Epstein- Barr virus and oncoproten expression in nasopharyngeal carcinoma in Korea. Head & Neck 2004;26:573- 583 https://doi.org/10.1002/hed.10370
  3. Jung YY, Kim OB, Kim JH. An analysis of prognostic factors affecting the outcome of radiation therapy for nasopharyngeal carcinoma. J Korean Soc Ther Radiol 2005; 23:71- 77
  4. Mendenhall WM, Riggs CE, Cassisi NJ. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2005:712- 713
  5. Sarraf MA, LeBlanc M, Girl PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310- 1317 https://doi.org/10.1200/JCO.1998.16.4.1310
  6. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression- free survival. J Clin Oncol 2003;21:631- 637 https://doi.org/10.1200/JCO.2003.06.158
  7. Nho YJ, Cho JG, Ahn SD, et al. Radiation therapy of nasopharyngeal carcinoma. J Korean Soc Ther Radiol 1997;15(4)
  8. Yun SM, Kim JC, Park IK. Combined modality treatment in nasopharyngeal carcinoma. J Korean Soc Ther Radiol 2001; 19:100- 106
  9. Lee MJ, Chun HC. Radiotherapy for nasopharyngeal carcinoma. J Korean Soc Ther Radiol 2003;21:269- 275
  10. Cho MJ, Jang JY, Kim JS, Kim BK, Song CJ, Kim JS. Results of radiation therapy in nasopharyngeal cancer. J Korean Soc Ther Radiol 2001;19:9- 15
  11. Lee JY, Loh JK, Suh CO, Lee YG, Hong WP. Radiotherapy results of nasopharyngeal carcinoma. J Korean Soc Ther Radiol 1988;6:13- 23
  12. Kao CH, Tsai SC, Wang JJ, Ho YJ, Yen RF, Ho ST. Comparing 18- Fluoro- 2- Deoxyglucose positron emission tomography with a combination of technetium 99m tetrofosmin single photon emission computed tomography and computed tomography to detect recurrent or persistent nasopharyngeal carcinomas after radiotherapy. Cancer 2001;92:434- 439 https://doi.org/10.1002/1097-0142(20010715)92:2<434::AID-CNCR1339>3.0.CO;2-O
  13. Greven KM, Williams DW III, McGuirt WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942- 946 https://doi.org/10.1002/hed.1136
  14. Yen TC, Lin CY, Wang HM, Huang SF, Liao CT. 18FFDG- PET For evaluation of the response to concurrent chemoradiation therapy with intensity- modulated radiation technique for stage T4 nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys 2006;65:1307- 1314 https://doi.org/10.1016/j.ijrobp.2006.02.031
  15. Liu SH, Chang JT, NG SH, Chan SC, Yen TC. Case report - false positive fluorine- 18 fluorodeoxy- D- glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Brit J Radiol 2004;77:257- 260 https://doi.org/10.1259/bjr/69516821
  16. Zheng XK, Chen LH, Wang QS, Wu FB. Influence of $[^{18}F]$ fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys 2006;65:1020-1025 https://doi.org/10.1016/j.ijrobp.2006.02.037
  17. Yao M, Buatti JM, Dornfeld KJ, et al. Can post- RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? In regard to Rogers, et al. (Int J Radiat Oncol Biol Phys 2004; 58:694- 697). Int J Radiat Oncol Biol Phys 2005;61:306- 307
  18. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 2005;58:535- 538 https://doi.org/10.1136/jcp.2004.021923
  19. Kim KB, Wu HG, Park SW, Kim CJ, Park CI. Expression of cyclooxygenase (COX)- 2 as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004;36:187- 191 https://doi.org/10.4143/crt.2004.36.3.187
  20. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase- 2 overexpression is a marker of poor prognosis in stage I non- small cell lung cancer. Clin Cancer Res 2001:7;861- 867
  21. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase- 2 expression and colorectal cancer. JAMA 1999:282;1254- 1257 https://doi.org/10.1001/jama.282.13.1254
  22. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase- 2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003:55;16- 20 https://doi.org/10.1016/S0360-3016(02)03821-X
  23. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase- 2 pathway and angiogenesis in head and neck squamous cell carcinoma. Human Pathology 2002;33:708- 714 https://doi.org/10.1053/hupa.2002.125376
  24. Chen WC, McBride WH, Chen SM, et al. Prediction of poor survival by cyclooxygenase- 2 in patients with T4 nasopharyngeal cancer treated by radiotherapy. Head & Neck 2005;27:503- 512 https://doi.org/10.1002/hed.20178
  25. Peng JP, Chang HC, Hwang CF, Hung WC. Overexpression of cyclooxygenase- 2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 2005;41:903- 908 https://doi.org/10.1016/j.oraloncology.2005.05.003
  26. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress: head and neck cancer. N Engl J Med 2001;345: 1890- 1990 https://doi.org/10.1056/NEJMra001375
  27. Niemhom S, Kitazawa S, Murao S, Kunachak S, Maeda S. Co- expression of p53 and bcl- 2 may correlate to the presence of Epstein- Barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Letters 2000;160:199- 208 https://doi.org/10.1016/S0304-3835(00)00582-6
  28. Sheu LF, Chen A, Lee HS, Hsu HY, Yu DS. Cooperative interactions among p53, bcl- 2 and Epstein- Barr virus latent membrane protein 1 in nasophayngeal carcinoma cells. Pathology International 2004;54:475- 485 https://doi.org/10.1111/j.1440-1827.2004.01654.x
  29. Yang HJ, Cho YJ, Kim SH, Chang MS, Sung MW, Kim HS. Association of p53 and Bcl- 2 expression with Epstein- Barr virus infection in the cancer of the head and neck. Head & Neck 2001;23:629- 636 https://doi.org/10.1002/hed.1089
  30. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S. Expression of bcl- 2- , p53, and Ki- 67 and outcome of patients with primary carcinoma following DNA damaging treatment. Head & Neck 1998;20:640- 644 https://doi.org/10.1002/(SICI)1097-0347(199810)20:7<640::AID-HED11>3.0.CO;2-K
  31. Sarac S, Akyol MU, Kanbur B, et al. Bcl- 2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol 2001;22:377- 382 https://doi.org/10.1053/ajot.2001.28071
  32. Khabir A, Ghorbel A, Daoud J, et al. Similar BCL- X but different BCL- 2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detection and Prevention 2003;27:250- 255 https://doi.org/10.1016/S0361-090X(03)00098-9
  33. Gasparin G, Bevilacqua P, Bonaldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with noncurrent chemotherapy. Clin Cancer Res 1995;1:1375- 1383
  34. Ho KY, Kuo WR, Chai CY, et al. A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma. The Laryngoscope 2001;111:131- 136 https://doi.org/10.1097/00005537-200101000-00023
  35. Ma BY, Poon TW, To KF, et al. Prognostic significance of tumor angiogenesis, Ki- 67, p53 oncoprotein, EGFR and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - prospective study. Head & Neck 2003;25:864- 872 https://doi.org/10.1002/hed.10307
  36. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of Bcl- 2 oncoprotein in EBVassociated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol 1997;12:9- 18
  37. Pezzela F, Turley H, Kuzu I, et al. Bcl- 2 protein in nonsmall- cell lung carcinoma. N Engl J Med 1993;329:690- 694 https://doi.org/10.1056/NEJM199309023291003
  38. Gallo O, Boddi V, Calzolari A, Simonetti L, Taroati M, Bianchi S. Bcl- 2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996;2:261- 267
  39. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21- 26 https://doi.org/10.1016/j.ijrobp.2003.10.027
  40. Eriksen JG, Steinichie T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor related to tumor differentiation and the overall treatment time of radiotherapy in sqamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561- 566 https://doi.org/10.1016/j.ijrobp.2003.09.043
  41. Chua DT, Nicholls JM, Sham JT, Au GH. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11- 20 https://doi.org/10.1016/j.ijrobp.2003.10.038
  42. Leong JL, Loh KS, Putti TC, Goh BC, Tan LKS. Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx. The Laryngoscope 2004;114: 153- 157 https://doi.org/10.1097/00005537-200401000-00029
  43. Putti TC, To KF, Hsu HC, et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicenter immunohistochemical study in the Asia- Pacific region. Histopathology 2002;41: 144- 151 https://doi.org/10.1046/j.1365-2559.2002.01436.x